IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Why It Matters

The deadline determines who can shape litigation strategy and potentially secure a larger recovery for investors harmed by alleged misstatements, a critical issue in the volatile biotech sector.

Key Takeaways

• Deadline to join IBRX class action: May 26, 2026.
• Investors bought IBRX Jan‑Mar 2026 may claim losses.
• Alleged false statements about Anktiva’s capabilities and trial results.
• Stock fell 12.13% to $6.45 after Phase 2 release.
• Contact Josh Wilson at Faruqi & Faruqi for representation.

Pulse Analysis

Class‑action lawsuits remain a primary tool for shareholders to seek redress after alleged corporate misstatements. In a federal securities case, the court‑appointed lead plaintiff must demonstrate the largest financial stake and typicality, while any class member can petition to become lead plaintiff before the May 26, 2026 deadline. Faruqi & Faruqi, a veteran securities‑litigation firm, has filed the complaint against ImmunityBio and is actively recruiting investors who purchased shares between January 19 and March 24, 2026. The firm’s outreach underscores the importance of timely participation, as lead‑plaintiff status can shape litigation strategy and potential recovery.

The complaint alleges that ImmunityBio’s CEO, Patrick Soon‑Shiong, overstated the capabilities of the company’s Anktiva platform and presented overly optimistic data from the Phase 2 QUILT 3.078 glioblastoma trial. When the January 23, 2026 press release disclosed that the primary endpoint—median overall survival—had not been reached, the stock plunged $0.89, a 12.13% drop to $6.45 per share. Plaintiffs argue that these statements violated federal securities laws by being materially false or lacking a reasonable basis, directly harming investors who entered the market on the promise of breakthrough results.

For investors, the May 26 deadline creates a narrow window to assert their rights and potentially influence the selection of a lead plaintiff who will steer settlement negotiations. Biotechnology firms like ImmunityBio are especially vulnerable to litigation because clinical data can swing valuations dramatically. As more biotech companies face heightened regulatory scrutiny, securities class actions are likely to increase, prompting shareholders to monitor disclosures closely. Contacting experienced counsel such as Josh Wilson at Faruqi & Faruqi can help investors evaluate claim viability, preserve evidence, and maximize any eventual recovery.